The turmoil on financial markets failed to derail Roche’s ambitions to buy Ventana Medical Systems, as peace broke out on Tuesday after the Swiss pharmaceuticals group made an improved offer for the US diagnostics company.

Roche raised its bid from $75 to $89.50 a share, valuing Arizona-based Ventana at $3.4bn, or $400m more than its repeatedly spurned initial offer.